Study of CM512 injection for chronic hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with chronic hives for at least 6 months.
- You must have had itching and hives for more than 6 weeks while taking antihistamines.
- You must be on a stable dose of a second-generation antihistamine for at least 7 days before starting.
- Your hives and itching scores must be moderate to severe (UAS7 at least 16 and ISS7 at least 8) in the week before randomization.
- You cannot be pregnant, breastfeeding, or planning to have children during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet (Alpha-0261) for chronic spontaneous urticaria (long-lasting hives without a clear cause). It aims to see if the drug is safe and tolerable. Part 1 includes people with chronic hives, and Part 2 looks at how food affects the drug in healthy adults.
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
This trial tests a new medication called THB335 for people with chronic spontaneous urticaria (CSU), which causes hives and itching for months without a clear cause. The study will see if the drug can reduce hives and itching better than a placebo (a pill with no active medicine).
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
This study tests a new drug, TLL-018, for people with moderate-to-severe chronic hives (CSU) that don't respond well to standard antihistamines. The goal is to see if it works quickly to reduce itching and hives.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.